Aleglitazar

Base Information

Chemical Name:Aleglitazar
CAS No.:475479-34-6
Molecular Formula:C24H23NO5S
Molecular Weight:437.516
Hs Code.:
UNII:41T4OAG59U
DSSTox Substance ID:DTXSID70197193
Wikipedia:Aleglitazar
Wikidata:Q3609417
NCI Thesaurus Code:C72687
Pharos Ligand ID:95U9DZRMC66K
Metabolomics Workbench ID:152000
ChEMBL ID:CHEMBL519504
Mol file:475479-34-6.mol

Synonyms:aleglitazar

Suppliers and Price of Aleglitazar

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Medical Isotopes, Inc.
Aleglitazar
25 mg
$ 1500.00

DC Chemicals
Aleglitazar >98%
10 mg
$ 295.20

DC Chemicals
Aleglitazar >98%
100 mg
$ 1120.00

ChemScene
Aleglitazar 99.30%
10mg
$ 950.00

ChemScene
Aleglitazar 99.30%
5mg
$ 650.00

ChemScene
Aleglitazar 99.30%
100mg
$ 3500.00

ChemScene
Aleglitazar 99.30%
50mg
$ 2500.00

Biorbyt Ltd
Aleglitazar
100 mg
$ 1683.00

Biorbyt Ltd
Aleglitazar
50 mg
$ 1203.60

Biorbyt Ltd
Aleglitazar
10 mg
$ 598.40

Total 46 raw suppliers

Chemical Property of Aleglitazar

Chemical Property:

Vapor Pressure:0mmHg at 25°C
Melting Point:146-147 °C
Refractive Index:1.627
Boiling Point:665.151 °C at 760 mmHg
PKA:3.54±0.46(Predicted)
Flash Point:356.071 °C
PSA：110.03000
Density:1.291 g/cm³
LogP:5.12830
XLogP3:5.1
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:9
Exact Mass:437.12969401
Heavy Atom Count:31
Complexity:586

Purity/Quality:

97% ^*data from raw suppliers

Aleglitazar ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC(C(=O)O)OC
Isomeric SMILES:CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC
Recent ClinicalTrials:A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone
Recent EU Clinical Trials:A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities
Use Description Aleglitazar is a pharmaceutical compound developed for its potential applications in the medical field, specifically in the treatment of cardiovascular diseases and diabetes. In the field of medicine, it has been studied for its role as a dual peroxisome proliferator-activated receptor (PPAR) agonist, which means it can simultaneously activate two types of PPAR receptors—PPAR-alpha and PPAR-gamma. This dual activation can have beneficial effects on lipid metabolism, insulin sensitivity, and glucose regulation, making it a candidate for the management of conditions like type 2 diabetes and dyslipidemia. However, it's important to note that as of my last knowledge update in September 2021, aleglitazar had faced challenges in clinical development due to safety concerns, particularly related to cardiovascular events. Therefore, its exact role and usage in the medical field were still under evaluation and required further research and regulatory approval. Please consult more recent sources for the latest information on aleglitazar's status and applications in the medical field.

Technology Process of Aleglitazar

There total 6 articles about Aleglitazar which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 100.0%

: 849150-55-6
(Z)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-acrylic acid

: 475479-34-6
[14C]-Aleglitazar

: 849150-59-0
(2R)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid

Guidance literature:: With sodium hydroxide; hydrogen; Ru(OAc)2((S)-(6-MeO-2-naphthyl)-MeOBIPHEP); In methanol; dichloromethane; water; at 40 ℃; for 24h; under 11251.1 Torr; Product distribution / selectivity;

Reference yield: 70.0%

: 849150-55-6
(Z)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-acrylic acid

: 475479-34-6
[14C]-Aleglitazar

Guidance literature:: With hydrogen; [Ir((S,S)-DBT-Bn-SIPHOX)(COD)]BARF; (S)-1-phenyl-ethylamine; In tetrahydrofuran; methanol; at 60 - 80 ℃; for 10h; under 22502.3 Torr; Product distribution / selectivity;

Reference yield:

: 475479-24-4
2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid

: 475479-34-6
[14C]-Aleglitazar

Guidance literature:: 2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid; With (S)-1-phenyl-ethylamine; In tetrahydrofuran; Reflux;

With hydrogenchloride; In water; ethyl acetate; at 20 ℃; for 1h;